Jane Street
NMRA icon

Jane Street’s Neumora Therapeutics NMRA Stock Holding History

Jane Street’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.1K Buy
+12,400
New +$23.6K ﹤0.01% 11194
2025
Q1 		– Sell
-209,200
Closed -$2.22M – 10228
2024
Q4 		$2.22M Buy
+209,200
New +$2.51M ﹤0.01% 3930

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jane Street's NMRA Position: Q2 2026 in Review

Jane Street reduced its Neumora Therapeutics (NMRA) stake by 69% in Q2 2026, selling an estimated $986K and leaving 229,930 shares worth $391K. The position accounts for ﹤0.01% of the portfolio, ranked #8589.

Jane Street first reported a position in NMRA in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.02M in Q4 2025. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Jane Street held 229,930 shares of Neumora Therapeutics worth $391K as of Q2 2026.
  • Jane Street sold 517,735 Neumora Therapeutics shares in Q2 2026, an estimated $986K.
  • Neumora Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #8589 holding.
  • Jane Street first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Jane Street's Neumora Therapeutics position peaked at $2.02M in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.